Aurobindo gets approval for Didanosine Delayed Release Cap

16108 Investors following Aurobindo Pharm. Share this News with them.

0

Like this story, share it with millions of investors on M3

Aurobindo gets approval for Didanosine Delayed Release Cap

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Aurobindo awarded INDIASTAR 08 for Packaging Excellence Aurobindo Pharma gets approval for Abacavir Sulfate tabs Aurobindo gets approval for Losartan Potassium tabs ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg

Didanosine Delayed Release Capsules is the generic version of Bristol Myer Squibb's Videx® EC (Didanosine) Delayed-release Capsules, 125mg, 200mg, 250mg and 400mg and is indicated for the treatment of HIV-1 infections in adults.

This is Aurobindo's 78th ANDA approval from the USFDA 

Sourced From: Aurobindo Pharma Limited